We have focused over the past 20 years on the putative wider impact of aberrant immunoglobulin (Ig) somatic hypermutation (SHM)-like processes also via ADAR1/ADAR2 deaminase A-to-I editors causing A-to-I(G) mutations in both RNA and DNA substrates across the cancer genome. Here, ADAR is linked to cancer.